

Name	ScheBo® • Biotech AG (Head office)
	ScheBo® • Biotech UK Ltd. ScheBo® • Biotech USA Inc.
Address/P.O. Box	Netanyastrasse 3
Postal Code/City	35394 Giessen
State	Hesse
Contact Person	Ursula Scheefers-Borchel, Ph.D. Hans Scheefers, Ph.D. René M. Kröger, Ph.D.
Telephone	+49-641-4996-0
Fax	+49-641-4996-77
Email	schebo@schebo.com
Website	www.schebo.com
Number of Employees	48
The academic staff has many years of experience in the research and development of diagnostics	
Founded (year)	1989
Areas of Activity	Development, production and marketing of diagnostics
Biological Patents	ScheBo® • Biotech AG holds many international patents in the above fields and owns a good intellectual property-position.
External Collaborations	ScheBo® • Biotech AG has academic alliances with several universities and university hospitals in Europe, the USA, Japan, Israel and Canada.
Awards and Certificates	1993 – Hessian Innovation Award of the MBG 1998 – Hessian Innovation Award of the MBG 2002 – “Hidden Champion 2002” 2002 – “Innovationspreis der deutschen Wirtschaft“ (4 certificates) 2004 – Among the finalists for the “Innovationspreis der deutschen Wirtschaft”

Company Profile

ScheBo® • Biotech AG is an innovative biotech company that is active in the fields of development, production and marketing of diagnostics. ScheBo® • Biotech AG's mission is to improve quality of health care by providing the best diagnostics with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION and SIMPLICITY.

ScheBo® • Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D., and Hans Scheefers, Ph.D.

Subsidiaries

ScheBo® • Biotech UK Ltd., founded: 1999
ScheBo® • Biotech USA Inc., founded: 2001

The Company


- is completely privately funded and independent,
- operates internationally,
- develops innovative diagnostics.

25 Years of Leading Innovations

R&D and manufacturing led to the successful launch and sales of the following products:

- ScheBo® • Pancreatic Elastase 1 Stool Test
- ScheBo® • Pancreatic Elastase 1 Serum Test
- ScheBo® • Tumor M2-PK™ EDTA Plasma Test*
- ScheBo® • Elastase Canine Test
- ScheBo® • Quick-Prep™
- ScheBo® • Tumor M2-PK™ Stool Test*
- ScheBo® • Brainostic™ GFAP ELISA
- ScheBo® • M2-PK Quick™ (lateral flow test)*
- ScheBo® • 2in1 combi (M2-PK + Hb)™ (lateral flow & ELISA test)*
- ScheBo® • Pancreas Elastase 1 Quick™ (lateral flow test)
- ScheBo® • Pancreas Elastase 1 Quick™ Canine (lateral flow test)
- ScheBo® • Hb Smart™

* www.metabolic-database.com



Unique Selling Proposition

Innovative diagnostics

1993 ScheBo® • Biotech AG launched the world's first non-invasive, cheap routine test procedure for monitoring the exocrine function of the pancreas. Today highly-regarded clinicians and medical text books regard the *ScheBo® • Pancreatic Elastase 1 ELISA*, based on two monoclonal antibodies, as the “gold-standard” for non-invasive pancreatic exocrine function testing. ScheBo® • Biotech AG is world market leader for this FDA-cleared product. In 2013 the *ScheBo® • Pancreas Elastase 1 Quick™* test has been introduced as a point of care rapid test for the fast and reliable diagnosis/exclusion of Exocrine Pancreatic Insufficiency. Continuous innovation and strong customer focus have made ScheBo® • Biotech AG a leading molecular diagnostic company.

Closing a gap

The *ScheBo® • Tumor M2-PK™ EDTA-Plasma Test* is the first test in the world which detects a metabolic state, specific to 11 cancer entities. The predictive value of Tumor M2-PK reflects tumour activity and aggressiveness. Thus, the *ScheBo® • Tumor M2-PK™ EDTA-Plasma Test* closes a gap in the clinical practice of cancer treatment management.

Fighting cancer, colorectal cancer screening

The *ScheBo® • Tumor M2-PK™ Stool Test* is the first test detecting pyruvate kinase in stool, an excellent biomarker for colorectal cancer screening. This test has a sensitivity of 85% and a specificity of 95%. In 2012, ScheBo® • Biotech launched *ScheBo® • 2in1 Quick™ (M2-PK+Hb)*, a brand new innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening. By simultaneously testing for M2-PK and haemoglobin (Hb), both non-bleeding and bleeding colorectal cancers and polyps can be detected.

Fighting BSE:

2000/2004 ScheBo® • Biotech AG launched the *ScheBo® • Brainostic™ Test*, which allows the detection of brain and spinal cord (risk material) in meat products.